These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Yokota S; Miyamae T; Imagawa T; Iwata N; Katakura S; Mori M; Woo P; Nishimoto N; Yoshizaki K; Kishimoto T Arthritis Rheum; 2005 Mar; 52(3):818-25. PubMed ID: 15751095 [TBL] [Abstract][Full Text] [Related]
6. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Herlin T Expert Rev Clin Immunol; 2012 Aug; 8(6):517-25. PubMed ID: 22992145 [TBL] [Abstract][Full Text] [Related]
7. Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis. Yokota S; Kishimoto T Expert Rev Clin Immunol; 2010 Sep; 6(5):735-43. PubMed ID: 20828281 [TBL] [Abstract][Full Text] [Related]
8. [Interleukin-6 as a pathogenic factor of systemic-onset juvenile idiopathic arthritis]. Yokota S Nihon Rinsho Meneki Gakkai Kaishi; 2008 Apr; 31(2):99-103. PubMed ID: 18446012 [TBL] [Abstract][Full Text] [Related]
9. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Woo P; Wilkinson N; Prieur AM; Southwood T; Leone V; Livermore P; Wythe H; Thomson D; Kishimoto T Arthritis Res Ther; 2005; 7(6):R1281-8. PubMed ID: 16277681 [TBL] [Abstract][Full Text] [Related]
10. Proinflammatory Cytokine Environments Can Drive Interleukin-17 Overexpression by γ/δ T Cells in Systemic Juvenile Idiopathic Arthritis. Kessel C; Lippitz K; Weinhage T; Hinze C; Wittkowski H; Holzinger D; Fall N; Grom AA; Gruen N; Foell D Arthritis Rheumatol; 2017 Jul; 69(7):1480-1494. PubMed ID: 28296284 [TBL] [Abstract][Full Text] [Related]
11. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? de Benedetti F; Martini A Arthritis Rheum; 2005 Mar; 52(3):687-93. PubMed ID: 15751082 [No Abstract] [Full Text] [Related]
12. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations. Woerner A; von Scheven-Gête A; Cimaz R; Hofer M Expert Rev Clin Immunol; 2015 May; 11(5):575-88. PubMed ID: 25843554 [TBL] [Abstract][Full Text] [Related]
13. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205 [TBL] [Abstract][Full Text] [Related]
14. [Effective application of anti-IL-6-monoclonal antibody for children with systemic-onset juvenile idiopathic arthritis]. Yokota S Nihon Rinsho Meneki Gakkai Kaishi; 2004 Feb; 27(1):22-7. PubMed ID: 15045812 [No Abstract] [Full Text] [Related]
15. Canakinumab for the treatment of systemic juvenile idiopathic arthritis. Grom AA Expert Rev Clin Immunol; 2014 Nov; 10(11):1427-35. PubMed ID: 25269376 [TBL] [Abstract][Full Text] [Related]
16. Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Adams A; Lehman TJ Curr Opin Rheumatol; 2005 Sep; 17(5):612-6. PubMed ID: 16093841 [TBL] [Abstract][Full Text] [Related]
17. Systemic Juvenile Idiopathic Arthritis. Lee JJY; Schneider R Pediatr Clin North Am; 2018 Aug; 65(4):691-709. PubMed ID: 30031494 [TBL] [Abstract][Full Text] [Related]
18. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis. Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108 [TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of systemic inflammatory diseases in childhood: "Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome". Yokota S; Kikuchi M; Nozawa T; Kanetaka T; Sato T; Yamazaki K; Sakurai N; Hara R; Mori M Mod Rheumatol; 2015 Jan; 25(1):1-10. PubMed ID: 24842480 [TBL] [Abstract][Full Text] [Related]
20. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis. Orrock JE; Ilowite NT Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1015-24. PubMed ID: 27367267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]